Investment
Features
FeesSafety
Academy
More
Pluang+

Compare iShares S&P GSCI Commodity-Indexed Trust ETF (GSG) vs Heron Therapeutics Inc (HRTX) Price & Performance

iShares S&P GSCI Commodity-Indexed Trust ETFTrade
Heron Therapeutics IncTrade

Price performance (Past 24H)

Key statistics

iShares S&P GSCI Commodity-Indexed Trust ETF vs Heron Therapeutics Inc — how do they compare? iShares S&P GSCI Commodity-Indexed Trust ETF trades at $32.65, while Heron Therapeutics Inc trades at $0.34 (market cap $61.47M). The key difference: iShares S&P GSCI Commodity-Indexed Trust ETF is trading nearer its 52-week high, Heron Therapeutics Inc nearer its low. Which is the better fit depends on your goals.

GSGHRTX
Sector
Commodities - Metals/AgricultureHealth
52-Week High
$34.77$1.49
52-Week Low
$22.06$0.32
Market Cap
$61.47M
Enterprise Value
$168.21M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

iShares S&P GSCI Commodity-Indexed Trust ETF

GSG trades at $32.65, up 1.02% today, with a bearish technical signal driven by moving averages. Recent news highlights its energy-centric commodity exposure, which fueled strong H1 2026 performance but faces volatility risks. Financial ratios are unavailable, limiting fundamental clarity.

Outlook is cautious due to sector volatility and geopolitical risks, with a recent downgrade to Hold. Opportunities lie in broad commodity exposure, but investors should weigh energy price swings and lack of current financial data against potential gains.

Heron Therapeutics Inc

HRTX trades at $0.3507, up 6.21% in the last 24 hours, but technical indicators signal a bearish trend overall. The company reported Q2 2026 revenue of $37.7 million, missing estimates, with a net loss per share of $0.03. Despite a high gross profit margin of 70.07%, negative net income and cash flow from operations highlight financial strain. Analyst consensus remains strongly bullish with 94.74% buy ratings, but recent news includes a Zacks Strong Sell designation on July 15, 2026.

The outlook is mixed: strong analyst support contrasts with weak earnings and bearish technicals. Investment opportunity lies in potential turnaround if revenue growth accelerates, but risks include persistent losses, competitive pressures, and reliance on financing activities. The stock faces significant downside if operational performance does not improve.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About iShares S&P GSCI Commodity-Indexed Trust ETF

GSG is a diversified commodity ETF that tracks the S&P GSCI Total Return Index. It provides exposure to a broad basket of futures, including energy, metals, and agriculture, with a significant weighting toward the energy sector.

Read more on GSG

About Heron Therapeutics Inc

Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.

Read more on HRTX